Ratings by Jones Trading (Boris Peaker)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/15/2026 | Elicio Therapeutics | ELTX | Downgrade | Hold (Buy) |
14.85 (3.98) |
-73.2% | Details | |
| 5/14/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Buy (N/A) |
13.94 (10.99) |
-21.16% | Details | |
| 5/6/2026 | OnKure Therapeutics Inc. | OKUR | Downgrade | Hold (Buy) |
4.52 (4.34) |
-3.98% | Details | |
| 4/28/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Whitehawk Therapeutics | WHWK | New Coverage | Buy (N/A) |
3.51 (4.39) |
25.07% | Details | |
| 4/6/2026 | Protara Therapeutics | TARA | New Coverage | Buy (N/A) |
5.11 (4.03) |
-21.14% | Details | |
| 4/6/2026 | Prime Medicine | PRME | New Coverage | Buy (N/A) |
3.32 (3.12) |
-6.02% | Details | |
| 4/6/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
8.89 (9.43) |
6.07% | Details | |
| 4/6/2026 | OnKure Therapeutics Inc. | OKUR | New Coverage | Buy (N/A) |
4.29 (4.52) |
5.36% | Details | |
| 4/6/2026 | Oncolytics Biotech | ONCY | New Coverage | Hold (N/A) |
0.96 (0.92) |
-4.17% | Details | |
| 4/6/2026 | Nuvation Bio Inc | NUVB | New Coverage | Buy (N/A) |
4.41 (6.46) |
46.49% | Details | |
| 4/6/2026 | Monopar Therapeutics | MNPR | New Coverage | Buy (N/A) |
55.13 (88.99) |
61.42% | Details | |
| 4/6/2026 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
14.84 (14.64) |
-1.35% | Details | |
| 4/6/2026 | IN8bio Inc. | INAB | New Coverage | Buy (N/A) |
1.44 (1.48) |
2.78% | Details | |
| 4/6/2026 | Enliven Therapeutics | ELVN | New Coverage | Buy (N/A) |
38.83 (47.77) |
23.02% | Details | |
| 4/6/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
10.65 (14.85) |
39.44% | Details | |
| 4/6/2026 | Editas Medicine | EDIT | New Coverage | Buy (N/A) |
2.67 (2.80) |
4.87% | Details | |
| 4/6/2026 | Day One Biopharmaceuticals | DAWN | New Coverage | Hold (N/A) |
21.45 (21.53) |
0.37% | Details | |
| 4/6/2026 | Curis | CRIS | New Coverage | Buy (N/A) |
0.55 (0.34) |
-38.18% | Details | |
| 4/6/2026 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
14.43 (17.65) |
22.31% | Details | |
| 4/6/2026 | Context Therapeutics | CNTX | New Coverage | Buy (N/A) |
2.72 (0.58) |
-78.68% | Details | |
| 4/6/2026 | CG Oncology | CGON | New Coverage | Buy (N/A) |
67.48 (68.72) |
1.84% | Details | |
| 4/6/2026 | CervoMed | CRVO | New Coverage | Buy (N/A) |
4.14 (3.26) |
-21.26% | Details | |
| 4/6/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Hold (N/A) |
4.29 (4.22) |
-1.63% | Details | |
| 4/6/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
21.47 (25.64) |
19.42% | Details | |
| 4/6/2026 | Beam Therapeutics Inc | BEAM | New Coverage | Buy (N/A) |
24.66 (33.90) |
37.47% | Details | |
| 4/6/2026 | aTyr Pharma | ATYR | New Coverage | Hold (N/A) |
0.85 (0.56) |
-34.12% | Details | |
| 4/6/2026 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
24.89 (32.02) |
28.65% | Details | |
| 4/6/2026 | Adicet Bio Inc. | ACET | New Coverage | Buy (N/A) |
6.99 (8.25) |
18.03% | Details |
